Evaxion Stock Surges on Positive Melanoma Vaccine Trial Results

Key Facts

1Evaxion stock surged following the release of positive three-year clinical trial data for its melanoma vaccine.

Evaxion Biotech stock surged following the release of positive three-year clinical trial data for its melanoma vaccine. Investing.com reported that the jump was triggered by successful long-term results from the company's personalized cancer vaccine candidate.

The stock trended higher during trading on October 19, 2026, as market participants reacted to the clinical milestone. The upward movement reflects continued growth in the company's research development within the biotechnology sector.